参考文献/References:
[1].黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗的建议-2018[J].中国心脏起搏与心电生理杂志,2018,32(4):315-368.
[2].January CT,Wann LS,Calkins H,et al.2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2019,74(1):104-132.
[3].Zhao Y,Lu Y,Qin Y.A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation[J].?Int J Cardiol,2018,270:167-171.
[4].Calkins H,Hindricks G,Cappato R,et al.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J].?Europace,2018,20(1):e1-e160.
[5].Khan AA,Lip GYH.The prothrombotic state in atrial fibrillation: pathophysiological and management implications[J].?Cardiovasc Res,2019,115(1):31-45.
[6].Martin AC,Godier A,Narayanan K,et al.Management of intraprocedural anticoagulation in patients on non-vitamin K antagonist oral anticoagulants undergoing catheter ablation for atrial fibrillation[J].Circulation,2018,138(6): 627-633.
[7].蒋靖波,钟国强.心房颤动导管消融中脑卒中和无症状脑梗死的预防[J].心血管病学进展,2015,36(6):743-747.
[8].Kirchhof P,Purmah Y,Verma A.Oral anticoagulation after catheter ablation of atrial fibrillation: caught in the attribution trap?[J].Eur Heart J,2015,36(5):267-269.
[9].Nogami A,Harada T,Sekiguchi Y,et al.Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial[J].?JAMA Netw Open,2019,2(4):e191994.
[10].Hohnloser SH,Camm J,Cappato R,et al.Uninterrupted edoxaban vs.Vitamin K antagonists for ablation of atrial fibrillation:the ELIMINATE-AF trial[J].Eur Heart J,2019,40(36):3013-3021.
[11].Di Biase L,Callans D,H?usler KG,et al.Rationale and design of AXAFA-AFNET 5:aninvestigator-initiated,randomized,open,blinded outcome assessment,multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation[J].Europace,2017,19(1):132-138.
[12].Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the first European snapshot survey on procedural routines for atrial fibrillation ablation (ESS-PRAFA)[J].Europace,2015,17(6):986-993.
[13].Nogami A,Harada T,Sekiguchi Y,et al.Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial[J].?JAMA Netw Open,2019,2(4):e191994.
[14].de Heide J ,Vroegh CJ,Bhagwandien RE,et al.Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation[J].?J Interv Card Electrophysiol,2018,53(3):341-346.
[15].Yu HT,Park J,Kim TH,et al.When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study[J].Eur Heart J,2019,40(19): 1531-1537.
[16].Gorla R,Dentali F,Crippa M,et al.Perioperative safety and efficacy of different anticoagulation strategies with direct oral anticoagulants in pulmonary vein isolation: a meta-analysis[J].JACC Clin Electrophysiol,2018,4(6):794-806.
[17].Gautam S,John RM,Stevenson WG,et al.Effect of therapeutic INR on activated clotting times,heparin dosage,and bleeding risk during ablation of atrial fibrillation[J].J Cardiovasc Electrophysiol,2011,22(3):248-254.
[18].Yamaji H,Murakami T,Hina K,et al.Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin[J].J Cardiovasc Electrophysiol,2018,29(6):835-843.
[19].Kishima H,Mine T,Fukuhara E,et al.A novel protocol for initial heparin administration during catheter ablation for atrial fibrillation in patients taking direct oral anticoagulants[J].Heart Vessels,2019,34(5):832-841.
[20].Cappato R,Marchlinski FE,Hohnloser SH,et al.Uninterrupted rivaroxaban vs.uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation[J].Eur Heart J,2015,36(28):1805-1811.
[21].Mizobuchi M,Funatsu A,Kobayashi T,et al.How minimally interrupted direct oral anticoagulants affect intraprocedural anticoagulation during atrial fibrillation ablation? Insights from a Japanese single-center retrospective study[J].?J Arrhythm,2019,35(5):716-724.
[22].Martin AC,Kyheng M,Foissaud V,et al.Activated clotting time monitoring during atrial fibrillation catheter ablation: does the anticoagulant matter?[J].J Clin Med,2020,9(2):E350.
[23].Calkins H,Willems S,Verma A,et al.Heparin dosing in uninterrupted anticoagulation with dabigatran vs.warfarin in atrial fibrillation ablation: RE-CIRCUIT study[J].Europace,2019,21(6):879-885.
[24].Deng L,Xiao Y,Hong H.Withdrawal of oral anticoagulants 3 months after successful radiofrequency catheter ablation in patients with atrial fibrillation:a meta-analysis[J] .Pacing Clin Electrophysiol,2018,41(11):1391-1400.
[25].Atti V,Turagam MK,Viles-Gonzalez JF,et al.Anticoagulation after catheter ablation of atrial fibrillation:is it time to discontinue in select patient population?[J].J Atr Fibrillation,2018,11(4):2092.
[26].Santarpia G,de Rosa S,Sabatino J,et al.Should we maintain anticoagulation after successful radiofrequency catheter ablation of atrial fibrillation? the need for a randomized study[J].Front Cardiovasc Med,2017,4:85.
[27].Yang WY,Du X,Jiang C,et al.The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study[J].?Europace,2020,22(1):90-99.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(8):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[12]赵磊 梁兆光.导管消融术后心房颤动复发的危险因素及预防[J].心血管病学进展,2019,(5):766.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.025]
ZHAO LeiLIANG Zhaoguang.Risk Factors and Prevention of Atrial Fibrillation Recurrence after Catheterablation[J].Advances in Cardiovascular Diseases,2019,(8):766.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.025]
[13]赵灿 吴永全.基于环肺静脉隔离的房颤导管消融策略选择治疗进展[J].心血管病学进展,2020,(12):1234.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.003]
ZHAO Can,WU Yongquan.Catheter Ablation Strategies for Atrial Fibrillation Based on Circumferential Pulmonary Vein Isolation[J].Advances in Cardiovascular Diseases,2020,(8):1234.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.003]
[14]刘玉辉 王盼盼 陈椿.心房颤动性心肌病临床研究进展[J].心血管病学进展,2020,(12):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
LIU Yuhui,WANG Panpan,CHEN Chun.Atrial Fibrillation-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(8):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
[15]白金龙 李洪仕 蔡衡.非瓣膜性心房颤动导管消融术后抗凝策略的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.201.01.000]
[16]那丞 黄织春.干预自主神经对心房颤动影响的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
NA Cheng,HUANG Zhichun.Effect of Autonomic Nerve Intervention on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):30.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[17]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(8):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
[18]袁明 谢瑞芹.导管消融对心房颤动患者生活质量影响的研究进展[J].心血管病学进展,2021,(10):884.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.005]
YUAN MingXIE Ruiqin.Effect of Catheter Ablation on Quality of Life in patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):884.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.005]
[19]邹永伟 胡小恋.左房低电压与心房颤动相关性的研究进展[J].心血管病学进展,2022,(3):211.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHOU Yongwei,H U Xiaolian.The Correlation Between Left Atrial Low-Voltage Area and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(8):211.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[20]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(8):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]